PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 12, 2026JAMA Dermatology0 citations

SIGLEC-1 Expression in a Cohort of Patients With Lupus Erythematosus Treated With Anifrolumab

View Full Paper
AHAlice HorisbergerBrigham and Women's HospitalKSKatharina ShawUniversity of PennsylvaniaRCRochelle CastilloBrigham and Women's Hospital

Key Points

  • This study aims to assess the effectiveness of SIGLEC-1 expression in monitoring response to anifrolumab treatment in lupus erythematosus patients.
  • Cohort study design
  • Measurement of SIGLEC-1 expression levels
  • Assessment of treatment response to anifrolumab
  • SIGLEC-1 expression correlated with treatment response
  • Higher levels indicate better response to anifrolumab

Abstract

This cohort study evaluates the usefulness of measuring SIGLEC-1 expression for tracking response to anifrolumab therapy in patients with lupus erythematosus.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Horisberger et al. (2026) studied this question.

synapsesocial.com/papers/698d6eca5be6419ac0d5498chttps://doi.org/10.1001/jamadermatol.2025.5920
Ask AI
Helpful
Bookmark
Share
View Full Paper